Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis

ConclusionIn biologic-na ïve patients with active PsA treated with guselkumab, achieving ER or DR was associated with durable improvements in selected PROs, including those of high importance to patients.Trial registrationClinicalTrials.gov (https://clinicaltrials.gov) NCT03158285; Registered: May 16, 2017.Key Points•At week 100, 65% and 76% of guselkumab-treated patients achieved enthesitis and dactylitis resolution (ER/DR).•Achieving ER was associated with achieving DR and vice versa through the end of study.•Achieving ER or DR was associated with durable and meaningful improvements in selected patient-reported outcomes.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research